Institutes
Refine
Year of publication
- 2021 (154) (remove)
Document Type
- Article (104)
- Doctoral Thesis (40)
- Contribution to a Periodical (4)
- Preprint (4)
- Book (2)
Has Fulltext
- yes (154)
Is part of the Bibliography
- no (154)
Keywords
- SARS-CoV-2 (6)
- Cell biology (5)
- RNA (5)
- NMR spectroscopy (4)
- Antimicrobial resistance (3)
- Cancer (3)
- NMR (3)
- X-ray crystallography (3)
- photochemistry (3)
- Alzheimer’s disease (2)
- Baird's rule (2)
- Biochemistry (2)
- Biophysical chemistry (2)
- COVID19-NMR (2)
- Cryoelectron microscopy (2)
- Endothelial cells (2)
- Enzyme mechanisms (2)
- G-quadruplexes (2)
- Inflammation (2)
- Permeation and transport (2)
- RNA modification (2)
- SiGe alloys (2)
- Solution NMR spectroscopy (2)
- accessibility switch (2)
- acetylcholine (2)
- actin (2)
- ankyrin (2)
- boswellic acids (2)
- cluster compounds (2)
- erythrocyte (2)
- excited state aromaticity (2)
- farnesoid X receptor (2)
- germanium (2)
- hippocampus (2)
- inflammation (2)
- inward proton pump (2)
- malaria (2)
- mass spectrometry (2)
- microbial rhodopsin (2)
- microdialysis (2)
- microscopy (2)
- non-alcoholic steatohepatitis (2)
- optogenetics (2)
- photolabile protecting groups (2)
- polypharmacology (2)
- rearrangements (2)
- rhodopsin (2)
- silicon (2)
- similarity measures (2)
- substituent effects (2)
- virulence factor (2)
- 1,3-diamine (1)
- 140Ce (1)
- 2D NMR spectroscopy (1)
- 2′-O-methylation (1)
- 3D electron diffraction (1)
- 5'-UTR (1)
- 5-lipoxygenase (1)
- 5′-UTR (1)
- 6-shogaol (1)
- 9-borafluorene (1)
- ADAR (1)
- Ab initio calculations (1)
- Adenosine A1 receptor (1)
- Akute lymphoblastische Leukämie (1)
- Alterung (1)
- Analytical chemistry (1)
- Angiogenesis (1)
- Arc protein (1)
- Armadillo repeat protein (1)
- Aurora kinase (1)
- Bacterial biofilm (1)
- Bacterial structural biology (1)
- Bindungsanalyse (1)
- Biopysikalische Chemie (1)
- Bärnighausen tree (1)
- B−B bonds (1)
- B−H bonds (1)
- CEST (1)
- CNP (1)
- COVID-19 (1)
- CXCL13 (1)
- CXCR5 (1)
- Caenorhabditis elegans (1)
- Cancer models (1)
- Catalysis (1)
- Cell division (1)
- Cellular neuroscience (1)
- Chemical modification (1)
- Colorectal cancer (1)
- Computational biology and bioinformatics (1)
- Covid19-nmr (1)
- Cy5.5 (1)
- DFT+MBD calculations (1)
- DNA (1)
- DNA conjugate (1)
- DNA recognition (1)
- DNP (1)
- DNP in solids (1)
- Daclatasvir (1)
- DiI (1)
- Diseases (1)
- Drug delivery systems (1)
- Faltungsdynamik (1)
- Fatty acid synthases (1)
- Festkörperstruktur (1)
- G-Quadruplex (1)
- G-quadruplex binders (1)
- GIIb/IIIa-receptor (1)
- Genetic engineering (1)
- Genetics (1)
- Guanylatzyklasen (1)
- HCV (1)
- HIV protease inhibitors (1)
- Herpes Simplex Virus Type 1 (HSV-1) (1)
- Image processing (1)
- In situ hybridization (1)
- In vitro wound models (1)
- Infectious diseases (1)
- Ion transport (1)
- K48-linked (1)
- K63-linked (1)
- KR2 (1)
- Kinetik (1)
- Knochenmarksmikromilieu (1)
- Leukaemia (1)
- Leukocytes (1)
- Lewis acid (1)
- Lipidinteraktion (1)
- MACS (1)
- MET receptor (1)
- Makrophagen (1)
- Massenspektrometrie (1)
- Mechanisms of disease (1)
- Membranes (1)
- Metabolism (1)
- Mitosis (1)
- Molecular Neuroscience (1)
- NASH (1)
- NMRI (1)
- NOESY (1)
- NPR2 (1)
- NS5A (1)
- Natural product (1)
- Natural products (1)
- Neuropathic pain (1)
- Nucleolar protein 14 (1)
- Oncogenes (1)
- Overhauser effect (1)
- PAC-1 (1)
- PC12APPsw (1)
- PDF-Global-Fit (1)
- PIM kinases (1)
- PLGA nanoparticles (1)
- PXRD (1)
- Pain behavior (1)
- Partial agonist (1)
- Patch-clamp (1)
- Photochemie (1)
- Pigment Green 7 (1)
- Polyketide synthases (1)
- Post-Hartree-Fock methods (1)
- Potassium channels (1)
- Protein biosynthesis (1)
- Protein engineering (1)
- Protein synthesis (1)
- Pseudocontact shift (1)
- Pulverdiffraktometrie (1)
- R values (1)
- RMN (1)
- RNA PT (1)
- RNA cleavage (1)
- RNA synthesis (1)
- RNA-binding proteins (1)
- RND (1)
- Repair (1)
- Rh(II) catalysis (1)
- Rietveld refinement (1)
- Röntgenstrukturanalyse (1)
- SEDDS (1)
- SL1 (1)
- SL5a (1)
- SMEDDS (1)
- SNEDDS (1)
- SNP (1)
- Saccharomyces cerevisiae (1)
- Schmerz (1)
- Semi-empiricalcalculations (1)
- Silafullerane (1)
- Silane (1)
- Silole (1)
- Sodium ion pump (1)
- Solution-state NMR (1)
- Stem-cell research (1)
- Structural biology (1)
- Structure refinement (1)
- TERRA RNA (1)
- Tetrelbindung (1)
- TgF344-AD (1)
- Theoretical chemistry (1)
- Transporters (1)
- Vioprolide A (1)
- Wound dressings (1)
- Wound infection (1)
- X-ray structure analysis (1)
- Xenocoumacin (1)
- Zingiber officinale Roscoe (1)
- Zolpidem; Food-effect, PBBM, PBPK (1)
- absolute quantification of RNA modifications (1)
- ab initio calculations (1)
- accessory proteins (1)
- adaptor mediated recruitment (1)
- additive manufacturing (1)
- adenosine–arginine conjugate (1)
- adenylyl cyclases (1)
- aging (1)
- anilinopyrimidine (1)
- antibiotic resistance (1)
- antisense technology (1)
- antiviral signaling (1)
- apoptosis (1)
- aptamer (1)
- aptamers (1)
- automated assignment (1)
- axon bifurcation (1)
- axon branching (1)
- baicalein (1)
- benzazepinone (1)
- bioavailability (1)
- biophysics (1)
- bioprinting (1)
- bisubstrate inhibitors (1)
- body-on-a-chip (1)
- bond activation (1)
- boryl anions (1)
- breast milk (1)
- brightness (1)
- c-Myc (1)
- cGKI (1)
- cGMP signalling (1)
- cMYC (1)
- capture (1)
- carbazole ligands (1)
- cell stress (1)
- cell-free protein synthesis (1)
- cellular uptake and localization (1)
- cerium (1)
- channelrhodopsin (1)
- chemical shift assignment (1)
- chemiluminescence (1)
- chemoenzymatic synthesis (1)
- co-crystal structure (1)
- combinatorial approaches (1)
- complex I (1)
- conductivity (1)
- confocal microscopy (1)
- continuous rotation (1)
- copper phthalocyanine (1)
- coumarin 6 (1)
- creams (1)
- cross-correlation functions (1)
- cross-section (1)
- curcumin (1)
- cyanines (1)
- cyclic nucleotide-gated channels (1)
- cycloaddition (1)
- cysteine reactivity (1)
- deep learning (1)
- dendritic spines (1)
- de novo design (1)
- dialysis (1)
- diazo compounds (1)
- diboranes (1)
- diffusion states (1)
- digestion artifact (1)
- dissolution (1)
- dorsal root ganglia (1)
- drug discovery (1)
- drug release (1)
- dynamic nuclear polarization (1)
- efflux pump (1)
- electron crystallography (1)
- electron transfer system (1)
- enamides (1)
- enzyme catalysis (1)
- enzyme kinetics (1)
- epitranscriptomics (1)
- extract (1)
- famotidine (1)
- flavolignan (1)
- fluidity (1)
- fluorescent labeling (1)
- fluorescent probes (1)
- folding landscapes (1)
- fragment screening (1)
- frankincense (1)
- gapmers (1)
- glucose (1)
- glutathione (1)
- glutathionylation (1)
- guanidine riboswitch (1)
- guanylyl cyclases (1)
- hTERT (1)
- hairpin polyamides (1)
- heart-on-a-chip (1)
- high-throughput sequencing (1)
- histamine (1)
- human milk (1)
- hydromethylthionine (1)
- immune system (1)
- in vivo neuroimaging (1)
- infant health (1)
- interface engineering (1)
- intracellular internalization (1)
- intrinsically disordered region (1)
- isopropanol (1)
- isotope labeling (1)
- itch (1)
- kidney-on-a-chip (1)
- kinetics (1)
- lactate (1)
- leucocytes (1)
- leukotriene A4 hydrolase (1)
- ligand design (1)
- ligases (1)
- light control (1)
- light-induced polymerization (1)
- lipid based formulation (1)
- lipid suspension (1)
- liposomes (1)
- liver fibrosis (1)
- liver-on-a-chip (1)
- lung-on-a-chip (1)
- maternal diet (1)
- mature milk (1)
- medicinal plant (1)
- memantine (1)
- membrane proteins (1)
- membrane receptors (1)
- memory consolidation (1)
- metabolic sydrome (1)
- metabolomics (1)
- metallo β lactamases (1)
- micro-physiological systems (1)
- microRNA (1)
- microsomal prostaglandin E2 (1)
- mitochondria (1)
- mitochondrial respiration (1)
- mixed valence compounds (1)
- molecular docking (1)
- molecular dynamics (1)
- molecular electronics (1)
- multi-objective optimization (1)
- multi-target drug (1)
- multiresistant bacteria (1)
- n_TOF (1)
- nanomedicine (1)
- natural compound synthesis (1)
- neural network (1)
- neurodegeneration (1)
- neuromuscular system (1)
- neurotropic virus (1)
- neutron (1)
- nitroindoles (1)
- nitrosylation (1)
- non-alcoholic fatty liver disease (1)
- nonstructural proteins (1)
- nuclear receptor (1)
- nucleoside analysis (1)
- nucleosynthesis (1)
- oligonucleotide (1)
- oncogene promoters (1)
- one-pot reaction (1)
- optogenetic (1)
- organs-on-a-chip (1)
- osteopontin (1)
- oxidative folding (1)
- pain (1)
- pair distribution function analysis (1)
- pair distribution functions (1)
- pancreatic cancer (1)
- peroxisome prolifer ators-activated receptor-γ (1)
- pharmacokinetics (1)
- photoacid (1)
- photocaging (1)
- photocycle (1)
- photoisomerization (1)
- phototherapeutic window (1)
- phytochromes (1)
- platelets (1)
- polymers (1)
- polyubiquitin (1)
- powder data (1)
- precipitation inhibitor (1)
- protein X-ray crystallography (1)
- protein capture (1)
- protein engineering (1)
- protein kinase inhibitor (1)
- protein-protein interactions (1)
- proton transfer (1)
- pseudouridylation (1)
- quantum yield (1)
- quercetin (1)
- reactive oxygen species (1)
- real-time NMR spectroscopy (1)
- red light (1)
- redox chemistry (1)
- release testing (1)
- resmetirom (1)
- resveratrol (1)
- rhodamine 123 (1)
- ribosomal exit tunnel (1)
- rivastigmine (1)
- s-process (1)
- self-assembled monolayers (1)
- self-initiated photografting and photopolymerization (1)
- semisolids (1)
- siRNAs (1)
- silibinin (1)
- silybin (1)
- single-molecule imaging (1)
- single-particle tracking (1)
- single-trajectory analysis (1)
- skin-on-a-chip (1)
- sodium alkoxide (1)
- solid-phase synthesis (1)
- solid-state NMR (1)
- solid-state NMR spectroscopy (1)
- soluble epoxide hydrolase (1)
- solvate (1)
- somatosensory system (1)
- spinal cord (1)
- spiro compounds (1)
- splice-modulating oligonucleotides (1)
- stability of fluorescent label (1)
- stereoselective synthesis (1)
- stress dependent RNA modification dynamics (1)
- structural biology (1)
- structural proteins (1)
- structure determination (1)
- structure-activity relationships (1)
- subvalent compounds (1)
- sulfamide (1)
- super-SMEDDS (1)
- super-SNEDDS (1)
- supersaturating drug delivery systems (1)
- supersaturation (1)
- surface modification (1)
- surface-initiated polymerization (1)
- swelling (1)
- synthase-1 (1)
- tetrapyrrole-binding photoreceptors (1)
- thermal stability (1)
- thiol inhibitors (1)
- thyroid hormone receptor (1)
- time-resolved spectroscopy (1)
- tissue distribution (1)
- tissue-plasma-ratio (1)
- toll-like receptor (1)
- topical formulations (1)
- total scattering technique (1)
- total scattering techniques (1)
- transient complex (1)
- ubiquitin-conjugating enzymes (1)
- ultrafast spectroscopy (1)
- validation (1)
- venetoclax (1)
Institute
- Biochemie, Chemie und Pharmazie (154)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (14)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (10)
- Medizin (8)
- Präsidium (6)
- Biowissenschaften (3)
- Physik (2)
- Exzellenzcluster Makromolekulare Komplexe (1)
- Geowissenschaften / Geographie (1)
- MPI für Biophysik (1)
Dimerization of Taspase1 activates an intrinsic serine protease function that leads to the catalytic Thr234 residue, which allows to catalyze the consensus sequence Q−3X−2D−1⋅G1X2D3D4, present in Trithorax family members and TFIIA. Noteworthy, Taspase1 performs only a single hydrolytic step on substrate proteins, which makes it impossible to screen for inhibitors in a classical screening approach. Here, we report the development of an HTRF reporter assay that allowed the identification of an inhibitor, Closantel sodium, that inhibits Taspase1 in a noncovalent fashion (IC50 = 1.6 μM). The novel inhibitor interferes with the dimerization step and/or the intrinsic serine protease function of the proenzyme. Of interest, Taspase1 is required to activate the oncogenic functions of the leukemogenic AF4-MLL fusion protein and was shown in several studies to be overexpressed in many solid tumors. Therefore, the inhibitor may be useful for further validation of Taspase1 as a target for cancer therapy.
Glucose hypometabolism, mitochondrial dysfunction, and cholinergic deficits have been reported in early stages of Alzheimer’s disease (AD). Here, we examine these parameters in TgF344-AD rats, an Alzheimer model that carries amyloid precursor protein and presenilin-1 mutations, and of wild type F344 rats. In mitochondria isolated from rat hippocampi, we found reductions of complex I and oxidative phosphorylation in transgenic rats. Further impairments, also of complex II, were observed in aged (wild-type and transgenic) rats. Treatment with a “cocktail” containing magnesium orotate, benfotiamine, folic acid, cyanocobalamin, and cholecalciferol did not affect mitochondrial activities in wild-type rats but restored diminished activities in transgenic rats to wild-type levels. Glucose, lactate, and pyruvate levels were unchanged by age, genetic background, or treatment. Using microdialysis, we also investigated extracellular concentrations of acetylcholine that were strongly reduced in transgenic animals. Again, ACh levels in wild-type rats did not change upon treatment with nutrients, whereas the cocktail increased hippocampal acetylcholine levels under physiological stimulation. We conclude that TgF344-AD rats display a distinct mitochondrial and cholinergic dysfunction not unlike the findings in patients suffering from AD. This dysfunction can be partially corrected by the application of the “cocktail” which is particularly active in aged rats. We suggest that the TgF344-AD rat is a promising model to further investigate mitochondrial and cholinergic dysfunction and potential treatment approaches for AD.
Background: In the past, protease inhibitors (PIs) and the reverse transcriptase inhibitor abacavir were identified increasing the risk for thromboembolic complications and cardiovascular events (CVE) of HIV infected patients taking a combination antiretroviral therapy (cART). Results of the previous HIV-PLA I-study lead to the assumption that platelet activation could play a substantial role in increasing CVE risks.
Methods: The open label, monocentric HIV-PLA II-study investigated HIV-1-infected, therapy-naïve adults (n=45) starting with cART, consisting either of boosted PI (atazanavir, n= 6, darunavir, n=11), NNRTI (efavirenz, n=14) or integrase inhibitor (raltegravir, n=14), each plus tenofovir/emtricitabine co-medication. Main exclusion criteria were tobacco smoking, the intake of NSAIDs or abacavir or past CVE. Platelet adhesive molecule p-selectin (CD62P) and FITC anti-human Integrin α-IIb/Integrin β-3 (CD41/CD61) antibody (PAC-1) binding, monocyte CD11b/monocyte-associated CD41 expression and the endogenous thrombin potential (ETP) were assessed ex vivo-in vitro at baseline, weeks 4, 12 and 24. Therapy regimens were blinded to the investigators for laboratory and statistical analyses.
Results: CD11b and ETP showed no significant changes or differences between all study groups. In contrast, the mean + SD mean fluorescence units (MFI) of CD62P and PAC-1 increased significantly in patients taking PI, indicating an enhanced potential for thrombocyte activation and aggregation.
Conclusion: CD62P expression, detecting the ɑ-platelet degranulation of pro-inflammatory and pro-thrombotic factors and adhesive proteins, and PAC-1 expression, representing a marker for conformation changes of the GIIb/IIIa receptor, increased significantly in patients taking HIV protease inhibitors. The findings of this study revealed a yet unknown pathway of platelet activation, possibly contributing to the increased risk for CVE under HIV protease inhibitor containing cART.
Clinical Trial Registration No.: DRKS00000288.
Antigen presentation via major histocompatibility complex class I (MHC I) molecules is essential to mount an adaptive immune response against pathogens and cancerous cells. To this end, the transporter associated with antigen processing (TAP) delivers snippets of the cellular proteome, resulting from proteasomal degradation, into the ER lumen. After peptide loading and editing by the peptide-loading complex (PLC), stable peptide-MHC I complexes are released for cell surface presentation. Since the process of MHC I trafficking is poorly defined, we established an approach to control antigen presentation by introduction of a photo-caged amino acid in the catalytic ATP-binding site of TAP. By optical control, we initiate TAP-dependent antigen translocation, thus providing new insights into TAP function within the PLC and MHC I trafficking in living cells. Moreover, this versatile approach has the potential to be applied in the study of other cellular pathways controlled by P-loop ATP/GTPases.
Currently, a wide variety of complex non-oral dosage forms are entering the global healthcare market. Although many assays have been described in recent research, harmonized procedures and standards for testing their in vitro performance remain widely unexplored. Among others, dialysis-based techniques such as the Pharma Test Dispersion Releaser are developed for testing the release of drugs from nanoparticles, liposomes, or extracellular vesicle preparations. Here, we provide advanced strategies and practical advice for the development and validation of dialysis-based techniques, including documentation, analysis, and interpretation of the raw data. For this purpose, key parameters of the release assay, including the hydrodynamics in the device at different stirring rates, the selectivity for particles and molecules, as well as the effect of excipients on drug permeation were investigated. At the highest stirring rate, a more than twofold increase in the membrane permeation rate (from 0.99 × 10−3 to 2.17 × 10−3 cm2/h) was observed. Additionally, we designed a novel computer model to identify important quality parameters of the dialysis experiment and to calculate error-corrected release profiles. Two hydrophilic creams of diclofenac, Voltaren® Emulgel, and Olfen® gel, were tested and provide first-hand evidence of the robustness of the assay in the presence of semisolid dosage forms.
Polo-like kinase 1 (PLK1) is a crucial regulator of cell cycle progression. It is established that the activation of PLK1 depends on the coordinated action of Aurora-A and Bora. Nevertheless, very little is known about the spatiotemporal regulation of PLK1 during G2, specifically, the mechanisms that keep cytoplasmic PLK1 inactive until shortly before mitosis onset. Here, we describe PLK1 dimerization as a new mechanism that controls PLK1 activation. During the early G2 phase, Bora supports transient PLK1 dimerization, thus fine-tuning the timely regulated activation of PLK1 and modulating its nuclear entry. At late G2, the phosphorylation of T210 by Aurora-A triggers dimer dissociation and generates active PLK1 monomers that support entry into mitosis. Interfering with this critical PLK1 dimer/monomer switch prevents the association of PLK1 with importins, limiting its nuclear shuttling, and causes nuclear PLK1 mislocalization during the G2-M transition. Our results suggest a novel conformational space for the design of a new generation of PLK1 inhibitors.
The prevention of tau protein aggregations is a therapeutic goal for the treatment of Alzheimer's disease (AD), and hydromethylthionine (HMT) (also known as leucomethylthioninium-mesylate [LMTM]), is a potent inhibitor of tau aggregation in vitro and in vivo. In two Phase 3 clinical trials in AD, HMT had greater pharmacological activity on clinical endpoints in patients not receiving approved symptomatic treatments for AD (acetylcholinesterase (AChE) inhibitors and/or memantine) despite different mechanisms of action. To investigate this drug interaction in an animal model, we used tau-transgenic L1 and wild-type NMRI mice treated with rivastigmine or memantine prior to adding HMT, and measured changes in hippocampal acetylcholine (ACh) by microdialysis. HMT given alone doubled hippocampal ACh levels in both mouse lines and increased stimulated ACh release induced by exploration of the open field or by infusion of scopolamine. Rivastigmine increased ACh release in both mouse lines, whereas memantine was more active in tau-transgenic L1 mice. Importantly, our study revealed a negative interaction between HMT and symptomatic AD drugs: the HMT effect was completely eliminated in mice that had been pre-treated with either rivastigmine or memantine. Rivastigmine was found to inhibit AChE, whereas HMT and memantine had no effects on AChE or on choline acetyltransferase (ChAT). The interactions observed in this study demonstrate that HMT enhances cholinergic activity in mouse brain by a mechanism of action unrelated to AChE inhibition. Our findings establish that the drug interaction that was first observed clinically has a neuropharmacological basis and is not restricted to animals with tau aggregation pathology. Given the importance of the cholinergic system for memory function, the potential for commonly used AD drugs to interfere with the treatment effects of disease-modifying drugs needs to be taken into account in the design of clinical trials.
Riboswitches are regulatory RNA elements that undergo functionally important allosteric conformational switching upon binding of specific ligands. The here investigated guanidine-II riboswitch binds the small cation, guanidinium, and forms a kissing loop-loop interaction between its P1 and P2 hairpins. We investigated the structural changes to support previous studies regarding the binding mechanism. Using NMR spectroscopy, we confirmed the structure as observed in crystal structures and we characterized the kissing loop interaction upon addition of Mg2+ and ligand for the riboswitch aptamer from Escherichia coli. We further investigated closely related mutant constructs providing further insight into functional differences between the two (different) hairpins P1 and P2. Formation of intermolecular interactions were probed by small-angle X-ray scattering (SAXS) and NMR DOSY data. All data are consistent and show the formation of oligomeric states of the riboswitch induced by Mg2+ and ligand binding.
The formation of amyloid-β oligomers plays a key role in the onset of Alzheimer’s disease. We investigated the aggregation of amyloid-β oligomers by mass spectrometry and ion mobility spectrometry, revealing those structural properties, which lead to the formation of mature fibrils. We can show that the arrangement of the first oligomers is crucial for the topology of the resulting species, leading to the formation of non-toxic aggregates or fibrils.
Herein, we present a multi-cycle chemoenzymatic synthesis of modified RNA with simplified solid-phase handling to overcome size limitations of RNA synthesis. It combines the advantages of classical chemical solid-phase synthesis and enzymatic synthesis using magnetic streptavidin beads and biotinylated RNA. Successful introduction of light-controllable RNA nucleotides into the tRNAMet sequence was confirmed by gel electrophoresis and mass spectrometry. The methods tolerate modifications in the RNA phosphodiester backbone and allow introductions of photocaged and photoswitchable nucleotides as well as photocleavable strand breaks and fluorophores.
Salt-inducible kinases (SIKs) are key metabolic regulators. Imbalance of SIK function is associated with the development of diverse cancers, including breast, gastric and ovarian cancer. Chemical tools to clarify the roles of SIK in different diseases are, however, sparse and are generally characterized by poor kinome-wide selectivity. Here, we have adapted the pyrido[2,3-d]pyrimidin-7-one-based PAK inhibitor G-5555 for the targeting of SIK, by exploiting differences in the back-pocket region of these kinases. Optimization was supported by high-resolution crystal structures of G-5555 bound to the known off-targets MST3 and MST4, leading to a chemical probe, MRIA9, with dual SIK/PAK activity and excellent selectivity over other kinases. Furthermore, we show that MRIA9 sensitizes ovarian cancer cells to treatment with the mitotic agent paclitaxel, confirming earlier data from genetic knockdown studies and suggesting a combination therapy with SIK inhibitors and paclitaxel for the treatment of paclitaxel-resistant ovarian cancer.
The nsP3 macrodomain is a conserved protein interaction module that plays essential regulatory roles in host immune response by recognizing and removing posttranslational ADP-ribosylation sites during SARS-CoV-2 infection. Thus, targeting this protein domain may offer a therapeutic strategy to combat the current and future virus pandemics. To assist inhibitor development efforts, we report here a comprehensive set of macrodomain crystal structures complexed with diverse naturally-occurring nucleotides, small molecules as well as nucleotide analogues including GS-441524 and its phosphorylated analogue, active metabolites of remdesivir. The presented data strengthen our understanding of the SARS-CoV-2 macrodomain structural plasticity and it provides chemical starting points for future inhibitor development.
G-quadruplexes (G4), found in numerous places within the human genome, are involved in essential processes of cell regulation. Chromosomal DNA G4s are involved for example, in replication and transcription as first steps of gene expression. Hence, they influence a plethora of downstream processes. G4s possess an intricate structure that differs from canonical B-form DNA. Identical DNA G4 sequences can adopt multiple long-lived conformations, a phenomenon known as G4 polymorphism. A detailed understanding of the molecular mechanisms that drive G4 folding is essential to understand their ambivalent regulatory roles. Disentangling the inherent dynamic and polymorphic nature of G4 structures thus is key to unravel their biological functions and make them amenable as molecular targets in novel therapeutic approaches. We here review recent experimental approaches to monitor G4 folding and discuss structural aspects for possible folding pathways. Substantial progress in the understanding of G4 folding within the recent years now allows drawing comprehensive models of the complex folding energy landscape of G4s that we herein evaluate based on computational and experimental evidence.
Age-related multifactorial diseases, such as the neurodegenerative Alzheimer’s disease (AD), still remain a challenge to today’s society. One mechanism associated with AD and aging in general is mitochondrial dysfunction (MD). Increasing MD is suggested to trigger other pathological processes commonly associated with neurodegenerative diseases. Silibinin A (SIL) is the main bioactive compound of the Silymarin extract from the Mediterranean plant Silybum marianum (L.) (GAERTN/Compositae). It is readily available as a herbal drug and well established in the treatment of liver diseases as a potent radical scavenger reducing lipid peroxidation and stabilize membrane properties. Recent data suggest that SIL might also act on neurological changes related to MD. PC12APPsw cells produce low levels of human Aβ and thus act as a cellular model of early AD showing changed mitochondrial function. We investigated whether SIL could affect mitochondrial function by measuring ATP, MMP, as well as respiration, mitochondrial mass, cellular ROS and lactate/pyruvate concentrations. Furthermore, we investigated its effects on the mitochondrial membrane parameters of swelling and fluidity in mitochondria isolated from the brains of mice. In PC12APPsw cells, SIL exhibits strong protective effects by rescuing MMP and ATP levels from SNP-induced mitochondrial damage and improving basal ATP levels. However, SIL did not affect mitochondrial respiration and mitochondrial content. SIL significantly reduced cellular ROS and pyruvate concentrations. Incubation of murine brain mitochondria with SIL significantly reduces Ca2+ induced swelling and improves membrane fluidity. Although OXPHOS activity was unaffected at this early stage of a developing mitochondrial dysfunction, SIL showed protective effects on MMP, ATP- after SNP-insult and ROS-levels in APPsw-transfected PC12 cells. Results from experiments with isolated mitochondria imply that positive effects possibly result from an interaction of SIL with mitochondrial membranes and/or its antioxidant activity. Thus, SIL might be a promising compound to improve cellular health when changes to mitochondrial function occur.
Dysfunction of YEATS-domain-containing MLLT1, an acetyl/acyl-lysine dependent epigenetic reader domain, has been implicated in the development of aggressive cancers. Mutations in the YEATS domain have been recently reported as a cause of MLLT1 aberrant reader function. However, structural basis for the reported alterations in affinity for acetyled/acylated histone has remained elusive. Here, we report the crystal structures of both insertion and substitution present in cancer, revealing significant conformational changes of the YEATS-domain loop 8. Structural comparison demonstrates that such alteration not only altered the binding interface for acetylated/acylated histones, but the sequence alterations in the T1 loop may enable dimeric assembly consistent inducing self-association behavior. Nevertheless, we show that also the MLLT1 mutants can be targeted by developed acetyllysine mimetic inhibitors with affinities similarly to wild type. Our report provides a structural basis for the altered behaviors and potential strategy for targeting oncogenic MLLT1 mutants.
The repertoire of natural products offers tremendous opportunities for chemical biology and drug discovery. Natural product-inspired synthetic molecules represent an ecologically and economically sustainable alternative to the direct utilization of natural products. De novo design with machine intelligence bridges the gap between the worlds of bioactive natural products and synthetic molecules. On employing the compound Marinopyrrole A from marine Streptomyces as a design template, the algorithm constructs innovative small molecules that can be synthesized in three steps, following the computationally suggested synthesis route. Computational activity prediction reveals cyclooxygenase (COX) as a putative target of both Marinopyrrole A and the de novo designs. The molecular designs are experimentally confirmed as selective COX-1 inhibitors with nanomolar potency. X-ray structure analysis reveals the binding of the most selective compound to COX-1. This molecular design approach provides a blueprint for natural product-inspired hit and lead identification for drug discovery with machine intelligence.
Mitochondrial NADH:ubiquinone oxidoreductase (complex I) is a 1-MDa membrane protein complex with a central role in energy metabolism. Redox-driven proton translocation by complex I contributes substantially to the proton motive force that drives ATP synthase. Several structures of complex I from bacteria and mitochondria have been determined, but its catalytic mechanism has remained controversial. We here present the cryo-EM structure of complex I from Yarrowia lipolytica at 2.1-Å resolution, which reveals the positions of more than 1600 protein-bound water molecules, of which ~100 are located in putative proton translocation pathways. Another structure of the same complex under steady-state activity conditions at 3.4-Å resolution indicates conformational transitions that we associate with proton injection into the central hydrophilic axis. By combining high-resolution structural data with site-directed mutagenesis and large-scale molecular dynamic simulations, we define details of the proton translocation pathways and offer insights into the redox-coupled proton pumping mechanism of complex I.
Cyclic GMP (cGMP) is a second messenger that regulates numerous physiological and pathophysiological processes. In recent years, more and more studies have uncovered multiple roles of cGMP signalling pathways in the somatosensory system. Accumulating evidence suggests that cGMP regulates different cellular processes from embryonic development through to adulthood. During embryonic development, a cGMP-dependent signalling cascade in the trunk sensory system is essential for axon bifurcation, a specific form of branching of somatosensory axons. In adulthood, various cGMP signalling pathways in distinct cell populations of sensory neurons and dorsal horn neurons in the spinal cord play an important role in the processing of pain and itch. Some of the involved enzymes might serve as a target for future therapies. In this review, we summarise the knowledge regarding cGMP-dependent signalling pathways in dorsal root ganglia and the spinal cord during embryonic development and adulthood, and the potential of targeting these pathways.
LINKED ARTICLES
This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc
Mixed-valence compounds as polarizing agents for overhauser dynamic nuclear polarization in solids
(2021)
Herein, we investigate a novel set of polarizing agents—mixed-valence compounds—by theoretical and experimental methods and demonstrate their performance in high-field dynamic nuclear polarization (DNP) NMR experiments in the solid state. Mixed-valence compounds constitute a group of molecules in which molecular mobility persists even in solids. Consequently, such polarizing agents can be used to perform Overhauser-DNP experiments in the solid state, with favorable conditions for dynamic nuclear polarization formation at ultra-high magnetic fields.
The concept of using precipitation inhibitors (PIs) to sustain supersaturation is well established for amorphous formulations but less in the case of lipid-based formulations (LBF). This study applied a systematic in silico–in vitro–in vivo approach to assess the merits of incorporating PIs in supersaturated LBFs (sLBF) using the model drug venetoclax. sLBFs containing hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyvinylpyrrolidone (PVP), PVP-co-vinyl acetate (PVP/VA), Pluronic F108, and Eudragit EPO were assessed in silico calculating a drug–excipient mixing enthalpy, in vitro using a PI solvent shift test, and finally, bioavailability was assessed in vivo in landrace pigs. The estimation of pure interaction enthalpies of the drug and the excipient was deemed useful in determining the most promising PIs for venetoclax. The sLBF alone (i.e., no PI present) displayed a high initial drug concentration in the aqueous phase during in vitro screening. sLBF with Pluronic F108 displayed the highest venetoclax concentration in the aqueous phase and sLBF with Eudragit EPO the lowest. In vivo, the sLBF alone showed the highest bioavailability of 26.3 ± 14.2%. Interestingly, a trend toward a decreasing bioavailability was observed for sLBF containing PIs, with PVP/VA being significantly lower compared to sLBF alone. In conclusion, the ability of a sLBF to generate supersaturated concentrations of venetoclax in vitro was translated into increased absorption in vivo. While in silico and in vitro PI screening suggested benefits in terms of prolonged supersaturation, the addition of a PI did not increase in vivo bioavailability. The findings of this study are of particular relevance to pre-clinical drug development, where the high in vivo exposure of venetoclax was achieved using a sLBF approach, and despite the perceived risk of drug precipitation from a sLBF, including a PI may not be merited in all cases.